|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,193,204: Compound Scope and Claim Landscape
U.S. Patent 8,193,204, titled "Substituted pyrrolo [2,3-d]pyrimidines as kinase inhibitors," was granted on June 5, 2012. The patent claims a genus of substituted pyrrolo[2,3-d]pyrimidine compounds and their use in treating various diseases, particularly those involving aberrant kinase activity. The core of the patent resides in its broad definition of chemical structures designed to inhibit specific kinase enzymes implicated in cancer and inflammatory conditions.
What is the core chemical structure claimed in U.S. Patent 8,193,204?
The patent claims a genus of compounds defined by Formula I:
R1
|
N==C--N
// \
C C--R2
\\ /
N==C
|
R3
wherein:
- R1 represents hydrogen, alkyl, or haloalkyl.
- R2 represents aryl or heteroaryl, where the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, substituted amino, hydroxyl, halo, acyl, and carboxyl.
- R3 represents aryl or heteroaryl, where the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, cyano, nitro, amino, substituted amino, hydroxyl, halo, acyl, and carboxyl.
The patent further specifies that the pyrrolo[2,3-d]pyrimidine core is optionally substituted at the 2-, 4-, 5-, 6-, and 7-positions. Specific preferred embodiments are detailed, including substituents at the 4- and 7-positions. For example, one embodiment specifies R1 as hydrogen, R2 as an optionally substituted phenyl ring, and R3 as an optionally substituted pyridyl or pyrimidinyl ring.
What specific kinase targets are implicated by the claimed compounds?
The patent identifies the claimed compounds as kinase inhibitors, specifically targeting kinases involved in cell signaling pathways. While the patent does not exhaustively list every single kinase, it broadly states their utility against "kinases," including but not limited to those involved in cancer, inflammation, and immunological disorders. The detailed description provides examples of kinase families that these compounds are intended to modulate, such as Janus Kinases (JAKs) and spleen tyrosine kinase (Syk). This broad targeting approach is designed to capture a wide range of potential therapeutic applications.
What is the geographic scope of U.S. Patent 8,193,204?
U.S. Patent 8,193,204 is exclusively a United States patent. Its legal protection and enforcement are limited to the territorial boundaries of the United States of America. This means that the patented compounds and their methods of use can be manufactured, used, sold, or imported within the U.S. without infringing this specific patent. Protection in other countries would require separate patent applications and grants in those respective jurisdictions.
How do the claims define the scope of protection?
The claims of U.S. Patent 8,193,204 are structured to define the boundaries of legal protection. Claim 1 is the broadest independent claim, covering the genus of compounds as described by Formula I. Subsequent dependent claims narrow the scope by specifying particular substituents or combinations of substituents, thereby providing protection for more defined subsets of the claimed chemical space. For instance, dependent claims may specify particular groups for R1, R2, and R3, or define substitutions on the pyrrolo[2,3-d]pyrimidine core.
The patent also includes claims directed to pharmaceutical compositions containing these compounds and methods of treating diseases by administering these compounds. These method-of-use claims are crucial for protecting the therapeutic applications of the patented molecules.
What is the prior art landscape for pyrrolo[2,3-d]pyrimidine kinase inhibitors?
The development of kinase inhibitors, particularly those based on the pyrrolo[2,3-d]pyrimidine scaffold, is a well-established area of pharmaceutical research. Prior art includes numerous publications and patents disclosing similar chemical structures and their kinase inhibitory activities. Key prior art would likely involve:
- Earlier patents: Disclosing related pyrrolo[2,3-d]pyrimidine derivatives with kinase inhibitory activity, potentially targeting different kinases or having variations in substitution patterns.
- Scientific literature: Research articles detailing the synthesis and biological evaluation of pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors for various therapeutic indications.
- Known kinase inhibitor drugs: Marketed drugs or those in clinical development that share the pyrrolo[2,3-d]pyrimidine core, such as tofacitinib (Xeljanz), which targets JAK kinases and is structurally related.
The novelty and inventiveness of U.S. Patent 8,193,204 would have been assessed against this backdrop of prior art during its examination by the U.S. Patent and Trademark Office (USPTO). Key distinctions would lie in specific substitution patterns, novel scaffolds within the genus, or unexpected efficacy against particular kinase targets.
What are the potential challenges or limitations of U.S. Patent 8,193,204?
The broad nature of the genus claim in U.S. Patent 8,193,204 can be a strength, but it also presents potential challenges:
- Prior Art Challenges: The existence of extensive prior art in the pyrrolo[2,3-d]pyrimidine space means that the patent's validity could be challenged based on prior disclosures that may have anticipated or rendered obvious some aspects of its claims.
- Infringement Analysis: Precisely defining infringement can be complex, especially when dealing with broad genus claims. Competitors may design around the patent by creating compounds that fall outside the precise language of the claims but achieve similar therapeutic effects.
- Enforcement Costs: Litigation to enforce a broad patent can be expensive and time-consuming, requiring substantial evidence to prove infringement.
- Claim Interpretation: The interpretation of claim language, particularly regarding the scope of "substituted," "aryl," and "heteroaryl" groups and their permitted substituents, can be subject to legal dispute.
How does this patent relate to existing approved drugs?
The pyrrolo[2,3-d]pyrimidine scaffold is a known pharmacophore in approved drugs. For example, Tofacitinib (Xeljanz), a JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, features this core structure. While U.S. Patent 8,193,204 claims a genus of compounds, its specific embodiments and the broader chemical space it covers may overlap with or be closely related to the structures of approved drugs or compounds in development by other pharmaceutical companies. A thorough freedom-to-operate analysis would be necessary to determine if specific compounds or their uses infringe upon this patent.
The patent's claims are designed to cover a range of structures that could potentially be developed into new therapeutic agents targeting kinase-mediated diseases. The broad scope implies that any future drug utilizing a compound within the defined Formula I, or a closely related derivative, could potentially fall under the patent's purview, subject to validity and infringement assessments.
Key Takeaways
- U.S. Patent 8,193,204 claims a broad genus of substituted pyrrolo[2,3-d]pyrimidine compounds designed as kinase inhibitors.
- The patent's geographic scope is limited to the United States.
- The claims encompass a chemical structure defined by Formula I, with varying substituents on the core scaffold and attached aryl/heteroaryl groups.
- The intended therapeutic targets include kinases implicated in cancer, inflammation, and immunological disorders, with specific mention of JAK and Syk kinases.
- The prior art landscape for pyrrolo[2,3-d]pyrimidine kinase inhibitors is extensive, posing potential challenges to patent validity and enforcement.
- Approved drugs like Tofacitinib share the pyrrolo[2,3-d]pyrimidine core, indicating a competitive therapeutic space.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 8,193,204?
U.S. Patent 8,193,204 was granted on June 5, 2012. Assuming no patent term extensions or adjustments, it would have a standard 20-year term from its filing date. The filing date for this patent was December 19, 2008. Therefore, its scheduled expiration is December 19, 2028.
-
Does this patent cover generic versions of existing drugs?
This patent claims a genus of compounds. If an existing drug's chemical structure falls within the specific definitions outlined in the patent's claims, then generic versions of that drug could potentially infringe this patent, provided the patent remains valid and enforceable. However, a specific structural analysis is required to confirm overlap.
-
Can I develop a drug that uses a compound covered by this patent in Europe?
U.S. Patent 8,193,204 provides protection only within the United States. Development and commercialization of a drug in Europe would not directly infringe this U.S. patent. However, European patent protection for similar compounds would need to be independently assessed.
-
What are the primary kinase families targeted by the compounds claimed in this patent?
While the patent broadly targets "kinases," it specifically mentions the Janus Kinases (JAKs) and spleen tyrosine kinase (Syk) as examples of implicated targets within its detailed description.
-
How broad is the definition of "substituted pyrrolo[2,3-d]pyrimidines" in Claim 1?
Claim 1 defines the core structure with broad options for substituents at R1, R2, and R3, which can be aryl or heteroaryl groups with various optional substitutions. The pyrrolo[2,3-d]pyrimidine core itself is also described as optionally substituted at multiple positions (2-, 4-, 5-, 6-, and 7-). This broad definition aims to cover a wide range of chemical variations on the pyrrolo[2,3-d]pyrimidine scaffold.
Citations
[1] U.S. Patent 8,193,204. (2012). Substituted pyrrolo [2,3-d]pyrimidines as kinase inhibitors. Issued June 5, 2012.
More… ↓
⤷ Start Trial
|
